The role of recombinant human elafin in the resistance of A549 cells against pseudomonas aeruginosa biofilm

Respiration

Volumn 79, Issue 1, 2009, Pages 68-75

  Li, Qi ^a   Zhou, Xiangdong ^a   Nie, Xiaohong ^a   Yang, Jie ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Biofilm; Elafin; Epithelial cells; Pseudomonas aeruginosa; Respiratory pathogens

Indexed keywords

ELAFIN; TUMOR NECROSIS FACTOR;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL COUNT; BIOFILM; CELL DAMAGE; CLINICAL ARTICLE; ESCHERICHIA COLI; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RESPIRATORY TRACT DISEASE;

AGED; BIOFILMS; CELL LINE, TUMOR; ELAFIN; EPITHELIAL CELLS; HUMANS; IMMUNITY, INNATE; MALE; MIDDLE AGED; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RECOMBINANT PROTEINS; RESPIRATORY MUCOSA; RNA, MESSENGER; TRANSFECTION;

EID: 73349102472     PISSN: 00257931     EISSN: None     Source Type: Journal    
DOI: 10.1159/000218154     Document Type: Article

References (47)

1. Costerton JW, Stewart PS, Greenberg EP: Bacterial biofilms: A common cause of persistent infections. Science 1999; 284: 1318-1322.
2. Van Eeden SF, Sin DD: Chronic obstructive pulmonary disease: A chronic systemic inflammatory disease. Respiration 2008; 75: 224-238.
3. Nseir S, Cavestri B, Di Pompeo C, Diarra M, Brisson H, Lemyze M, Roussel-Delvallez M, Durocher A: Factors predicting bacterial involvement in severe acute exacerbations of chronic obstructive pulmonary disease. Respiration 2008; 76: 253-260.
4. Dwyer TM, Farley JM: Human neutrophil elastase releases two pools of mucinlike glycoconjugate from tracheal submucosal gland cells. Am J Physiol Lung Cell Mol Physiol 2000; 2789:L675-L682.
5. Abdi-Ali A, Mohammadi-Mehr M, Agha Alaei Y: Bactericidal activity of various antibiotics against biolfilm-producing Pseudomonas aeruginosa . Int J Antimicrob Agents 2006; 27: 196-200.
6. Sallenave JM, Silva A: Characterization and gene sequence of the precursor of elafin, an elastase-specific inhibitor in bronchial secretions. Am J Respir Cell Mol Biol 1993; 8: 439-445.
7. Hiemstra PS: Novel roles of protease inhibitors in infection and inflammation. Biochem Soc Trans 2002; 30: 116-120.
8. Tremblay GM, Vachon E, Larouche C, Bourbonnais Y: Inhibition of human neutrophil elastase-induced acute lung injury in hamsters by recombinant human pre-elafin (trappin-2). Chest 2002; 121: 582-588.
9. Simpson AJ, Maxwell AI, Govan JR, Haslett C, Sallenave JM: Elafin (elastase-specific inhibitor) has anti-microbial activity against gram-positive and gram-negative respiratory pathogens. FEBS Lett 1999; 452: 309-313.
10. Hoiby N, Krogh Johansen H, Moser C, Song Z, Ciofu O, Kharazmi A: Pseudomonas aeruginosa and the in vitro and in vivo biofilm mode of growth. Microbes Infect 2001; 3: 23-25.
11. Passariello C, Berlutti F, Selan L, Thaller MC, Pezzi R: A rapid staining procedure to demonstrate glycocalyx production and bacterial biofilms. New Microbiol 1994; 17: 225-230.
12. Gebran SJ, Newton CA, Yamamoto Y, Klein TW, Friedman H: A rapid colorimetric assay for evaluating Legionella pneumophila growth in macrophages in vitro. J Clin Microbiol 1994; 32: 127-130.
13. Stephens C: Microbiology: Breaking down biofilms. Curr Biol 2002; 12:R132-R134.
14. Yanagihara K, Tomono K, Sawai T, Miyazaki Y, Hirakata Y, Kadota J, Kohno S: Combination therapy for chronic Pseudomonas aeruginosa respiratory infection associated with biofilm formation. J Antimicrob Chemother 2000; 46: 69-72.
15. Wilson M: Bacterial biofilms and human disease. Sci Prog 2001; 84: 235-254.
16. Schaaf B, Wieghorst A, Aries SP, Dalhoff K, Braun J: Neutrophil inflammation and activation in bronchiectasis: Comparison with pneumonia and idiopathic pulmonary fibrosis. Respiration 2000; 67: 52-59.
17. Henzter M, Teitzel GM, Balzer GJ, Heydorn A, Molin S, Givskov M, Parsek MR: Alginate overproduction affects Pseudomonas aeruginosa biofilm structure and function. J Bacteriol 2001; 183: 5395-5401.
18. Bavington C, Page C: Stopping bacterial adhesion: A novel approach to treating infections. Respiration 2005; 72: 335-344.
19. Lechtzin N, John M, Irizarry R, Merlo C, Diette GB, Boyle MP: Outcomes of adults with cystic fibrosis infected with antibioticresistant Pseudomonas aeruginosa . Respiration 2006; 73: 27-33.
20. Schalkwijk J, Wiedow O, Hirose S: The trappin gene family: proteins defined by an Nterminal transglutaminase substrate domain and a C-terminal four-disulphide core. Biochem J 1999; 340: 569-577.
21. Guyot N, Zani ML, Maurel MC, Dallet-Choisy S, Moreau T: Elafin and its precusor trappin-2 still inhibit neutrophil serine proteinases when they are covalently bound to extracellular matrix proteins by tissue transglutaminase. Biochemistry 2005; 44: 15610-15618.
22. Sallenave JM, Silva A, Marsden ME, Ryle AP: Secretion of mucus proteinase inhibitor and elafin by Clara cell and type II pneumocyte cell lines. Am J Respir Cell Mol Biol 1993; 8: 126-133.
23. Vachon E, Bourbonnais Y, Bingle CD, Rowe SJ, Janelle MF, Tremblay GM: Anti-inflammatory effect of pre-elafin in lipopolysaccharide-induced acute lung inflammation. Biol Chem 2002; 383: 1249-1256.
24. Tanaka N, Fujioka A, Tajima S, Ishibashi A, Hirose S: Elafin is induced in epidermis in skin disorders with dermal neutrophilic infiltration: interleukin-1 and tumour necrosis factor-alpha stimulate its secretion in vitro. Br J Dermatol 2000; 143: 728-732.
25. van Wetering S, van der Linden AC, van Sterkenburg MA, de Boer WI, Kuijpers AL, Schalkwijk J, Hiemstra PS: Regulation of SLPI and elafin release from bronchial epithelial cells by neutrophil defensins. Am J Physiol Lung Cell Mol Physiol 2002; 278: L51-L58.
26. Reid PT, Marsden ME, Cunningham GA, Haslett C, Sallenave JM: Human neutrophil elastase regulates the expression and secretion of elafin (elastase-specific inhibitor) in type II alveolar epithelial cells. FEBS Lett 1999; 457: 33-37.
27. Higashimoto Y, Yamagata Y, Iwata T, Ishiguchi T, Okada M, Masuda M, Satoh H, Itoh H: Adenoviral E1A suppresses secretory leukoprotease inhibitor and elafin secretion in human alveolar epithelial cells and bronchial epithelial cells. Respiration 2005; 72: 629-635.
28. Meyer-Hoffert U, Wichmann N, Schwichtenberg L, White PC, Wiedow O: Supernatants of Pseudomonas aeruginosa induce the Pseudomonas-specific antibiotic elafin in human keratinocytes. Exp Dermatol 2003; 12: 418-425.
29. Melby K, Toews GB, Pierce AK: Pulmonary elastase activity in response to Streptococcus pneumoniae and Pseudomonas aeruginosa . Am Rev Respir Dis 1985; 131: 559-563.
30. Nobar SM, Zani ML, Boudier C, Moreau T, Bieth JG: Oxidized elafin and trappin poorly inhibit the elastolytic activity of neutrophil elastase and proteinase 3. FEBS J 2005; 272: 5883-5893.
31. Schwank S, Rajacic Z, Zimmerli W, Blaser J: Impact of bacterial biofilm formation in vitro and in vivo activities of antibiotics. Antimicrob Agents Chemother 1998; 42: 895-898.
32. McMichael JW, Maxwell AI, Hayashi K, Taylor K, Wallace WA, Govan JR, Dorin JR, Sallenave JM: Antimicrobial activity of murine lung cells against Staphylococcus aureus is increased in vitro and in vivo after elafin gene transfer. Infect Immun 2005; 73: 3609-3617.
33. Hiemstra PS, Maassen RJ, Stolk J: Antibacterial activity of antileukoprotease. Infect Immun 1996; 64: 4520-4524.
34. Ohbayashi H: Novel neutrophil elastase inhibitors as a treatment for neutrophil-predominant inflammatory lung diseases. Drugs 2002; 5: 910-923.
35. Simpson AJ, Wallace WA, Marsden ME, Govan JR, Porteous DJ, Haslett C, Sallenave JM: Adenoviral augmentation of elafin protects the lung against acute injury mediated by activated neutrophils and bacterial infection. J Immunol 2001; 167: 1778-1786.
36. Baranger K, Zani ML, Chandenier J, Dallet-Choisy S, Moreau T: The antibacterial and antifungal properties of trappin-2 (pre-elafin) do not depend on its protease inhibitory function. FEBS J 2008; 275: 2008-2020.
37. Williams SE, Brown TI, Roghanian A, Sallenave JM: SLPI and elafin: One glove, many fingers. Clin Sci 2006; 110: 21-35.
38. Sallenave JM: The role of secretory leukocyte proteinase inhibitor and elafin (elastase-specific inhibitor/skin-derived antileukoprotease) as alarm antiproteases in inflammatory lung disease. Respir Res 2000; 1: 87-92.
39. Henriksen PA, Hitt M, Xing Z, Wang J, Haslett C, Riemersma RA, Webb DJ, Kotelevtsev YV, Sallenave JM: Adenoviral gene delivery of elafin and secretory leukocyte protease inhibitor attenuates NF-- B-dependent inflammatory responses of human endothelial cells and macrophages to atherogenic stimuli. J Immun 2004; 172: 4535-4544.
40. Butler MW, Robertson I, Greene CM, O'Neill SJ, Taggart CC, McElvaney NG: Elafin prevents lipopolysaccharide-induced AP-1 and NF-B activation via an effect on the ubiquitin-proteasome pathway. J Biol Chem 2006; 281: 34730-34735.
41. McMichael JW, Roghanian A, Jiang L, Ramage R, Sallenave JM: The antimicrobial antiproteinase elafin binds to lipopolysaccharide and modulates macrophage responses. Am J Respir Cell Mol Biol 2005; 32: 443-452.
42. Henriksen PA, Devitt A, Kotelevtsev Y, Sallenace JM: Gene delivery of the elastase inhibitor elafin protects macrophages from neutrophil elastase-mediated impairment of apoptotic cell recognition. FEBS Lett 2004; 574: 80-84.
43. Roghanian A, Williams SE, Sheldrake TA, Brown TI, Oberheim K, Xing Z, Howie SE, Sallenave JM: The antimicrobial/elastase inhibitor elafin regulates lung dendritic cells and adaptive immunity. Am J Respir Cell Mol Biol 2006; 34: 634-642.
44. Blasi F, Tarsia P, Aliberti S: Strategic targets of essential host-pathogen interactions. Respiration 2005; 72: 9-25.
45. Fitch PM, Roghanian A, Howie SE, Sallenave JM: Human neutrophil elastase inhibitors in innate and adaptive immunity. Biochem Soc Trans 2006; 34: 279-282.
46. Barnes PJ: Future advances in COPD Therapy. Respiration 2001; 68: 441-448.
47. Sallenave JM: Antimicrobial activity of antiproteinase. Biochem Soc Trans 2002; 30: 111-115.